New Two-Pronged drug joins fight against advanced cervical cancer
NCT ID NCT07232654
Summary
This study is testing whether adding a new immunotherapy drug called QL1706 to the standard treatment of chemotherapy and radiation works better for women with locally advanced cervical cancer. The drug aims to help the body's immune system fight the cancer. Researchers will enroll about 30 participants to see if this combination is safe and can better control the cancer and prevent it from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.